HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

LFWD

Lifeward Ltd. (NASDAQ)

Healthcare — Medical Devices

Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.

None 2 analysts
$7.69
+$0.03 (+0.39%)
Target: $20.00 (160.1%)
Sign in to add LFWD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$21.64M
P/E Ratio (TTM)-
Forward P/E-4.32
EPS (TTM)$-18.33
Dividend Yield-
Profit Margin-123.66%
Revenue Growth-22.10%
ROE-209.10%
Debt/Equity140.11
Recommendation None
Analyst Target$20.00
Analysts2
Indexes NASDAQ

Technical Indicators

RSI (14)65.0
Beta0.37
SMA 20-
SMA 40-
52-Week High$10.98
52-Week Low$4.14
50-Day Avg$7.08
200-Day Avg$7.27
Avg Volume8.8K
Volume8.3K

Performance Analysis

NEUTRAL

LFWD presents a mixed picture with both positive and negative indicators.

~ Trading at 52% of its 52-week range.
+ RSI at 65.0 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Revenue declined 22.1% year-over-year.
- Operating at a loss with -123.7% margin.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $20.00 implies 160.1% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:18 UTC

Back to Screener Export Report